NHGRI/DIR Technology Transfer Program

NHGRI/DIR 技术转让计划

• 批准号: 7734926
• 负责人: Eric Green
• 金额: $ 124.05万
• 依托单位: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7734926
• 关键词: Acute; African Trypanosomiasis; Agonist; Agreement; Anemia; Antibodies; Applications Grants; Award; BRCA1 gene; BRCA2 Mutation; Biological; Biological Sciences; Canis familiaris; Cell Line; Chagas Disease; Charcot-Marie-Tooth Disease; Chromosome Mapping; Chronic Myeloid Leukemia; Clinical Trials; Collaborations; Cooperative Research and Development Agreement; Copyright; Counseling; Cutaneous Melanoma; Cystic Kidney Diseases; Data; Detection; Development; Diagnosis; Diagnostic; Disease; Educational Materials; Electronics; Employee; Ensure; ErbB4 gene; Family; Fellowship; Frequencies; Funding; Genes; Genetic; Gifts; Human; Inclusion Bodies; Inherited; Intellectual Property; International; Kidney Diseases; Laboratory Research; Laws; Legal; Legal patent; Length; Licensing; Malignant - descriptor; Malignant Childhood Neoplasm; Malignant Neoplasms; Marketing; Matrix Metalloproteinases; Mediation; Methods; Mission; Muscular Atrophy; Mutagens; Mutate; Mutation; Myeloid Leukemia; Myopathy; Myotonic Dystrophy; NCOA3 gene; Neutrophil Collagenase; Nonprofit Organizations; Oxadiazoles; Oxides; PDE4B; Pharmacologic Substance; Plasmids; Policies; Private Sector; Process; Protein Kinase; Protein Tyrosine Phosphatase; Public Health; Pyruvate Kinase; Reagent; Reporting; Research; Research Project Grants; Resources; Schistosomiasis; Science Policy; Smith Magenis syndrome; Squamous cell carcinoma; Standards of Weights and Measures; Steroid Receptors; Technology; Technology Transfer; Testing; Therapeutic Agents; Thyrotropin Receptor; Title; Transitional Cell Carcinoma; United States National Institutes of Health; Universities; Water; clinical phenotype; commercialization; cruzain; dephostatin; gene therapy; human disease; inhibitor/antagonist; instrument; malignant breast neoplasm; mannosamine; melanoma; methylmalonic aciduria; novel; phosphatase inhibitor; phosphoric diester hydrolase; prognostic; programs; rhodesain; small molecule; symposium; tool

The Technology Transfer Office (TTO) facilitates interactions between NHGRI's research laboratories and other research entities, including universities, non-profit organizations and companies, for the benefit of public health. TTO carries out its mission by assisting in the transfer of NHGRI-developed technologies to the private sector for further development and commercialization and by managing formal relationships with pharmaceutical and life sciences companies through the use of various legal instruments. The TTO also ensures the speedy and efficient exchange of research resources between NHGRI and outside scientific groups and assures compliance with relevant laws and policies. 10 employee invention reports (EIRs) were processed and evaluated in FY2008 and six new patent applications have been filed to date. Example EIR titles are as follows: cell line for detection of genotoxin; substituted oxadiazole 2-oxides as a treatment of schistosomiasis; gene therapy for methylmalonic acidemia; substituted triazincs as inhibitors of Cruzain and Rhodesain and as front line therapies for Chagas Disease and African Trypanosomiasis; small molecule activators of human pyruvate kinase; thyroid stimulating hormone receptor agonists; analysis of the protein kinase family reveals a high frequency of mutations in ERBB4 in melanoma; analysis of the matrix metalloproteinase family reveals MMP-8 is often mutated in melanoma; dephostatin derivatives and protein tyrosine phosphatase inhibitors as inhibitors of human tryosyl-DNA phosphodiesterase (Tdp1); and inhibitors of PDE4A, PDE4B and PDE4D. New FY2008 executed conditional gift fund agreements and awarded non-NIH research fellowships focused on the following human disease research topics: cutaneous malignant melanoma; methylmalonic acidemia (MMA); Charcot-Marie Tooth disease; acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML); Smith-Magenis syndrome; medullary cystic kidney disease (MCKD); Cooleys anemia; breast cancer (specifically identification of novel genetic factors contributing to clinical phenotypes in large families with BRCA1 and BRCA2 mutations); and Myotonic Dystrophy Type DM1. In addition, we received research awards and donations to support several canine-focused research projects including: squamous cell carcinoma in the standard poodle; malignant histiocystosis (MH) in the Bernese Mountain Dog; mapping of the gene for transitional cell carcinoma in the Scottish Terrier and West Highland White Terrier; and Identifying genes regulating Addisons disease in the Portuguese Water Dog. In FY2008 we executed several new licenses involving the following technologies and patent-pending inventions: an antibody (AIB1, a novel steroid receptor co-activator) and a plasmid (pASP-l, the full-length pASP construct (pASP-I0.7, containing the NACP-Repl locus) for use as research reagents; and two patent applications (entitled Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating and/or predicting diseases and other biological states" and "Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers") for use in the development of childhood cancer diagnostic and prognostic tests. We received in a license application for the use of N-acetyl mannosamine (ManNAc) as a therapeutic agent to treat Hereditary Inclusion Body Myopathies (HIBM) and other muscular atrophies as well as hyposialyation kidney disorders.

技术转移办公室(TTO)促进NHGRI的研究实验室与其他研究实体(包括大学、非营利组织和公司)之间的互动，以造福公众健康。TTO履行其使命，协助将NHGRI开发的技术转让给私营部门，以便进一步开发和商业化，并通过使用各种法律文书管理与制药和生命科学公司的正式关系。TTO还确保NHGRI与外部科学团体之间快速有效地交换研究资源，并确保遵守相关法律和政策。 2008财年处理和评估了10份员工发明报告(EIR)，迄今已提交了6项新的专利申请。例如：用于检测基因毒素的细胞系；用于治疗血吸虫病的取代恶二唑2-氧化物；用于甲基丙二酸血症的基因治疗；作为Cruzain和Rhodesain的抑制剂以及用于治疗恰加斯病和非洲锥虫病的一线药物的取代的三嗪；人丙酮酸激酶的小分子激活剂；促甲状腺激素受体激动剂；对蛋白激酶家族的分析显示在黑色素瘤中ERBB4发生高频突变；对基质金属蛋白酶家族的分析发现在黑色素瘤中经常发生突变；脱磷蛋白衍生物和蛋白酪氨酸磷酸酶抑制物作为人酪氨酸磷酸二酯酶的抑制物(TDp1)；以及PDE4A、PDE4B和PDE4D的抑制物。 新的2008财年执行了有条件的捐赠基金协议，并授予了专注于下列人类疾病研究主题的非NIH研究奖学金：皮肤恶性黑色素瘤；甲基丙二酸血症(MMA)；夏科特-玛丽·托斯病(Charcot-Marie Tooth)；急性髓细胞白血病(AML)和慢性粒细胞白血病(CML)；Smith-Magenis综合征；髓样囊性肾病(MCKD)；库莱斯贫血；乳腺癌(特别是在带有BRCA1和BRCA2突变的大家庭中发现导致临床表型的新基因因素)；以及强直性肌营养不良DM1型。此外，我们还获得了研究奖项和捐款，以支持几个以犬类为重点的研究项目，包括：标准贵宾犬的鳞状细胞癌；伯恩山犬的恶性组织细胞增生症(MH)；苏格兰梗和西高地白梗的移行细胞癌基因图谱；以及葡萄牙水犬的Addisons病调控基因。 在2008财年，我们执行了几项新的许可，涉及以下技术和正在申请专利的发明：抗体(AIB1，一种新型的类固醇受体共激活剂)和质粒(pASP-L，全长pASP-I0.7，包含 NACP-Repl基因座)作为研究试剂；以及两项专利申请(标题为分析高维数据以分类、诊断、预测和/或预测疾病和其他生物状态的方法“和”基因选择及其用于诊断和靶向治疗选定癌症的方法“)，用于开发儿童癌症诊断和预后测试。我们收到了将N-乙酰甘露糖胺(ManNAc)用作治疗遗传性包涵体肌病(HIBM)和其他肌肉萎缩病以及肾功能低下症的治疗药物的许可证申请。